AstraZeneca have announced that they are to open their new global research and development headquarters at Cambridge Biomedical Campus, reports PharmaTimes Online.
The £330 million investment is set to bring 2,000 jobs to the area through the new facility by 2016 and aims to establish AstraZeneca as a global biopharmaceutical innovator. The Campus will be the site of biologics research, done by MedImmune, a branch of AstraZeneca, which already employs 500 people in Cambridge. The facility will be also focus on medicinal chemistry and is set to become the company’s centre for oncology research.
Pascal Soriot, AstraZeneca’s CEO, believes this move is an “exciting prospect” and that it reaffirms “AstraZeneca’s longstanding commitment to the UK.” David Willets MP adds to this, believing it to be “excellent news for the UK life sciences industry [as it] strengthens our global competitiveness.”
Looking for a job in this sector?